Low Float Squeeze Candidates
Watchlist note · Early October 2026
Residual vs. dormant: five micro-cap squeeze setups, ranked
MEDS is the name I would watch hardest. MYSZ is the one that still looks dormant. Neither is a buy signal.
I keep a short list of tiny Nasdaq names where the short interest, the borrow market, and the chart are telling different stories. The mistake with that list is treating every high short-interest print as a coiled spring. Some of these already sprung. Some never had the interest to spring. A few are sitting in the awkward middle: still expensive to borrow, still heavily shorted, and no longer in the middle of the volume event.
That middle is what this note is about. Rankings are my read as of early October 2026, not a model output and not a price target.
The ranking
| Rank | Ticker | Setup | My read |
|---|---|---|---|
| 1 | MEDS | Strongest residual | Best leftover squeeze structure, but already proved it can move, and it is violent |
| 2 | MYSZ | Dormant | High short interest, quiet chart, needs volume |
| 3 | BMGL | Used | High short interest, but the first squeeze already happened |
| 4 | WETO | Messy | Interesting borrow pressure, unreliable share-count data |
| 5 | WAFU | Pass | Mostly disqualified by low short interest |
Chart links open TradingView. Symbol pages are linked again under each name.
What the ranking is actually sorting
I am not ranking these by how much they might go up. I am ranking them by how cleanly they still fit a squeeze scanner after the obvious move is stripped out.
- Residual means the first squeeze already printed, the stock collapsed, and the borrow market is still unusually tight.
- Dormant means the short interest is real, the float is small, and there has not yet been a giant volume event that would say the squeeze already happened.
- Disqualified means the headline story is not supported by the short data.
Float, short interest, and days-to-cover do not agree across vendors. Where two sources conflict, I say so. A 35% short-float print and a 24% print can both be “high” and still be the wrong number for sizing a trade.
1. MEDS — active watch, not a fresh coil
DataMeds AI, Inc. symbol page · Open the MEDS chart
MEDS is the most interesting of the five, and also the easiest to misread.
The recent snapshot I am using, mostly from ChartExchange, looks like this:
- Price in the $3.60–$3.80 area
- Float around 1.05 million shares
- Short interest of 430,628 shares, about 40.97% of that float
- Borrow fee around 576% in the latest fee snapshot
- Only about 15,000 shares available to borrow in that same snapshot
- 30-day average volume around 12.2 million shares
- 30-day average fails-to-deliver around 11,788
- Still up roughly 298% over 30 days, even after the pullback
TradingView’s own statistics page has shown a larger float figure than ChartExchange. That gap matters. If the tradable float is meaningfully above 1.05 million, the short-interest percentage is lower than 41%, even if the share count short stays the same. I treat 41% as a vendor print, not as a settled fact.
The enormous caveat is the chart. The first squeeze already happened.
Into mid-September, MEDS ran from about $0.90 to $1.62, then to a $6.07 close, then to a $12.31 intraday high on September 15–16. September 16 alone traded about 188.8 million shares. That is not a dormant name waiting for its first move. Anyone describing MEDS as an untouched coil is describing a stock that no longer exists.
What is left is narrower, and more interesting for a scanner than a fresh-squeeze story:
A heavily shorted stock that already demonstrated squeeze capability, subsequently collapsed, and still has extraordinarily expensive borrow and a large reported short position.
That is a possible second squeeze, or a continuation squeeze, if a fresh catalyst brings volume back. It is not a prediction that one will happen. Borrow at several hundred percent can also mean the locate market is broken, the stock is hard to hedge, or both. Expensive borrow is a condition, not a catalyst.
The settlement is a real corporate item, not a meme
On September 17, 2026, DataMeds AI filed an 8-K describing a settlement of litigation tied to the May 11, 2023 Wellgistics membership-interest purchase agreement. The company paid $450,000 in total. Of that, $350,000 was attributed to the repurchase and extinguishment of 364,099 common shares, and $100,000 to the compromise of the related claims. The company said it anticipated extinguishing about $19 million of liabilities carried on the consolidated balance sheet. The related Florida and Delaware cases were to be dismissed with prejudice.
Primary documents, not recaps:
- MEDS Form 8-K, September 17, 2026
- Company press release via Access Newswire / AP
- TradingView news summary of the same filing
Retiring 364,099 shares is relevant to a 1 million-share float story. It is not, by itself, a reason the stock has to reclaim $5. Balance-sheet cleanups in micro-caps often arrive next to dilution, halts, or both. The filing is worth reading. It is not a trading system.
2. MYSZ — the cleaner dormant candidate
My Size, Inc. symbol page · Open the MYSZ chart
MYSZ fits the original scanner idea better than MEDS does, because it has not just finished a 188-million-share day.
The latest official-style short-interest snapshot I am using:
- Short interest around 181,375 shares
- ChartExchange short float around 35.39%, on a float near 512,000 shares
- Days to cover around 1
- Price around $1.60
- 30-day average volume around 1.18 million
- Market cap only around $1.1 million
Another provider has put short interest nearer 24% of float. I would not build a position on the difference between 24 and 35. Either print is substantial for a stock this small. Neither print is a timetable.
The borrow history is the part that keeps it on the list. In a September snapshot, Interactive Brokers showed a borrow fee around 114.6% with only about 35,000 shares available. Fees like that come and go. A stock can be expensive to borrow on Tuesday and locatable on Thursday. Still, a triple-digit fee on a half-million-share float is not noise.
Structure cuts both ways. My Size implemented a 1-for-8 reverse split effective after the close on August 12, 2026, specifically to support the Nasdaq bid-price requirement. Outstanding shares were expected to fall from about 4.8 million to about 600,000. The company’s reverse-split release is the clean source. Reverse splits create optically tight floats. They also mark companies that have already failed a listing standard.
Then, in September, the company sold about $2.50 million of pre-funded warrants and accompanying Series C and Series D warrants at a combined $1.91, in a private placement first sold on September 15, 2026. Proceeds were for general corporate purposes, including working capital. That financing is both a data point and a supply zone. The Form D summary is the place to start; the filing itself is the document that counts.
What I like. Tiny float. High short percentage on more than one methodology. Historically expensive borrow. Price depressed near $1.60. No recent giant volume event that would say the squeeze already occurred.
What I do not like. The $1.91 financing is overhead, not a footnote. The company has needed capital. Days-to-cover is low because volume can explode, which means shorts can also cover faster than a multi-day squeeze narrative assumes. Warrant overhang can turn a squeeze into a supply event.
3–5. Used, messy, or simply not short enough
BMGL — Basel Medical Group
High short interest is not enough once the first squeeze has already happened. BMGL stays on the list as a reference name, not as a fresh setup. A stock that has already taught the market it can move is a different trade from a stock the market has not tested. Third place is a demotion, not a hidden favorite.
WETO — Wetour Robotics
Borrow pressure here is interesting enough to keep the ticker visible. The share-count data is not. When float, outstanding shares, and short-interest percentage cannot be reconciled without a footnote, I do not promote the name. Messy denominators produce fake squeeze math.
WAFU — Wah Fu Education Group
WAFU is mostly disqualified by low short interest. A low-float story without a real short base is a volatility story, sometimes a dilution story, and not a squeeze story. I would rather miss a random spike than keep a name on this list that fails the premise.
What would change the ranking
MEDS moves up from “active watch” to “the dormant phase is over” only if it reclaims $4.00 with volume and then holds $4.65–$5.00. It moves down if borrow normalizes, the short-interest update shows the September spike was the cover, or the float data resolves higher.
MYSZ moves from dormant to active only through $2.00 on expanding volume, with the $1.91 financing area already tested rather than simply gapped. It comes off the list if the next short-interest report collapses, or if warrant exercise turns the tiny float into a supply pipe.
BMGL, WETO, and WAFU do not get promoted on price alone. They need cleaner data, not a green day.
A note on the data
Prices, borrow fees, shares available, and short-interest percentages in this note are point-in-time scanner reads from early October 2026. Short interest is reported with a lag. Borrow inventory can change in minutes. Fails-to-deliver are not the same thing as naked shorting. Average volume after a squeeze is inflated by the squeeze itself, which is why MEDS can show a huge 30-day average and still be quiet on an ordinary session.
TradingView links for the five names, chart first:
- NASDAQ:MEDS chart · symbol page
- NASDAQ:MYSZ chart · symbol page
- NASDAQ:BMGL chart · symbol page
- NASDAQ:WETO chart · symbol page
- NASDAQ:WAFU chart · symbol page
Disclaimer
This post is for education and commentary only. It is not investment, tax, legal, or accounting advice, and it is not an offer or solicitation to buy or sell any security. I am not your adviser, and I am not acting as a broker-dealer, investment adviser, or fiduciary.
MEDS, MYSZ, BMGL, WETO, and WAFU are speculative micro-cap stocks. They can halt, gap through stops, fail listing standards, dilute existing holders, or lose most or all of their value. Short selling these names can produce losses greater than the capital committed. Options, if any, can expire worthless. Leverage makes all of that worse.
Figures for price, float, short interest, days to cover, borrow fee, shares available, volume, and fails-to-deliver come from public market-data vendors and company filings available at the time of writing. Vendors disagree. Filings can be amended. Past squeezes, including the September 2026 move in MEDS, do not predict a second move. Levels mentioned above ($3.80, $4.00, $4.65, $5.00, $1.60, $1.91, $2.00, $2.20) are personal chart markers, not targets, recommendations, or guarantees.
Company filings linked here, including the DataMeds AI 8-K and the My Size reverse-split and Form D materials, should be read in full. Press-release summaries and news recaps can omit risk factors. I may be long, short, or uninvolved in any name mentioned, and that status can change without an update to this post. Assume I have no obligation to update it.
Do your own research, check the primary filings, and consider whether you can afford a total loss before trading any of these stocks. If you need advice, talk to a licensed adviser who knows your situation.
Comments
Post a Comment